Bolt Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bolt Biotherapeutics, Inc. on June 6, 2025. The report details a corporate action regarding the Company's capital structure, specifically the implementation of a reverse stock split.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the amendment to the Certificate of Incorporation.
Material Changes
- Reverse Stock Split: Effective June 6, 2025, the Company executed a one-for-twenty (1:20) reverse stock split.
- Share Conversion: Every 20 shares of issued and outstanding common stock were automatically converted into one share.
- Equity Plans: The split adjusted the number of shares available under equity incentive plans and employee stock purchase plans.
- Options and RSUs: The number of shares issuable upon exercise of outstanding stock options and restricted stock units was reduced, with a corresponding increase in the exercise price per share.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
- Trading Details: Common stock began trading on a split-adjusted basis on the Nasdaq Capital Market on June 9, 2025, under the ticker symbol "BOLT". The new CUSIP number is 097702203.
- Par Value: The par value per share remains unchanged at $0.00001.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, or contingencies beyond the description of the reverse stock split mechanics. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the new CUSIP number (097702203) for post-split trading.
- Confirm the adjusted share count and exercise prices for any held stock options or RSUs.
- Check for cash payments received in lieu of fractional shares.
- Review the trading status on the Nasdaq Capital Market starting June 9, 2025.